
Federal Trade Commission urged to investigate pharmacy benefit managers to uncover anticompetitive practices which raise drug prices for consumers

Joining other consumer organizations, PIRG submitted comments to the Federal Trade Commission (FTC) to recommend a broad investigation into the anticompetitive practices used by pharmacy benefit managers (PBMs). PBMS are the companies that manage the prescription drug portion of a health insurer’s benefits package. Our comments pointed out that “[i]n the past decade, PBM profits have more than doubled and increased to $28 billion annually.”
We urged the FTC to conduct a deep dive investigation into the PBM industry to “capture allegations of widespread fraudulent and deceptive practices.” Immediate attention by the FTC is necessary because the “PMB industry has avoided antitrust scrutiny for far too long.”
Photo Credit: Chris Potter on Flickr
See the Campaign

High Value Health Care
Topics
Updates

Energy Conservation & Efficiency
2.3 million families used efficiency tax credit to reduce energy costs in 2023

Energy Conservation & Efficiency
Efficiency tax credits helped 350,000 new homes be more energy efficient in 2023

Airline baggage fees: Court blocks disclosure of prices up front, for now

Energy Conservation & Efficiency
Energy Department finalizes efficiency standards for tankless water heaters
